Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lovaza for Non-Alcoholic Fatty Liver Disease
NCT00941642Phase 4Unknown
- Sponsor
- Huntington Medical Research Institutes
- Start
- Sep 2009
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial in non-alcoholic fatty liver disease (NAFLD) comparing Lovaza with Placebo (2 arms). Primary endpoints: Fibrosis Score at 48 weeks and NASH Activity Index at 48 weeks. Status: unknown.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT00941642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00941642.